Last reviewed · How we verify
Intravesical Solution
Intravesical Solution, marketed by Ankara Training and Research Hospital, is positioned as a treatment for BCG-refractory CIS of the urinary bladder. The key strength lies in its specific indication for a challenging patient population, with a key composition patent expiring in 2028. The primary risk is the limited revenue data and lack of detailed clinical trial results, which may affect market adoption and competitive positioning.
At a glance
| Generic name | Intravesical Solution |
|---|---|
| Also known as | Continuous Epirubicin Instillation During the Early Postoperative Period, Single-Dose Epirubicin Instillation During the Early Postoperative Period, Intravesical gemcitabin and docetaxel |
| Sponsor | Ankara Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- BCG-refractory CIS of the urinary bladder
Common side effects
- Urinary Frequency
- Dysuria
- Urinary Urgency
- Bladder Spasm
- Hematuria
- Bladder Pain
- Urinary Incontinence
- Cystitis
- Urinary Tract Infection
- Nocturia
- Local Burning Symptoms
- Abdominal Pain
Serious adverse events
- Pneumonia
- Anemia
- Fever
- Vomiting
- Vasodilation
- Chest Pain
- Rash
Key clinical trials
- Early vs Delayed Intravesical Blad-Care During BCG Therapy (NA)
- Bladder Directed vs. Pelvic Floor Therapy in IC/BPS (PHASE2)
- S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer (PHASE3)
- A Window of Opportunity Phase I Study of UGN-201 in Patients With Bladder Cancer Undergoing Radical Cystectomy Protocol #: 2021-0630 (PHASE1)
- Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer (PHASE4)
- Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (PHASE3)
- A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections (PHASE4)
- Evaluation of Safety and Efficacy of Phage Therapy for Drug-resistant Bacterial Infections: An Exploratory, Prospective Single-arm Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravesical Solution CI brief — competitive landscape report
- Intravesical Solution updates RSS · CI watch RSS
- Ankara Training and Research Hospital portfolio CI